Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Margarita Garrido Siles"'
Autor:
Mariola Sirvent-Ochando, Ana Murcia-Lopez, Cristina Sangrador-Pelluz, Sara Espla, Margarita Garrido-Siles, Jimena Abiles
Publikováno v:
Farmacia Hospitalaria, Vol 45, Iss 03, Pp 109-114 (2021)
The maximum expression of malnutrition in cancer patients is cancerous cachexia, always linked to an unfavorable prognosis. Given its evolutionary nature it is recommended to detect and act early in those patients with nutritional risk. The objective
Autor:
Beatriz Mora Rodríguez, María Carmen Martínez Díaz, Juan Francisco Marín Pozo, Begoña Muros de Fuentes, Paz Quesada Sanz, Fátima Artime Rodríguez-Hermida, María José Martínez Bautista, Úrsula Baños Roldán, José Carlos Roldán Morales, Patricia Rodríguez Gómez, María Teresa Garrido Martínez, Ana I. Sánchez, Juan Manuel Duarte Pérez, Macarena Merino Almazán, Rosa Villatoro Roldán, Antonio Rueda Ramos, Ángel Inoriza Rueda, José Miguel García, Margarita Garrido Siles, Pablo Nieto Guindo, Ana Laura Ortega Granados, Silvia Maria Artacho Criado
Publikováno v:
International Journal of Clinical Pharmacy. 41:272-279
Background Immunotherapy has become a standard treatment for lung cancer; however, the high cost makes it necessary to assess health outcomes. Objective The aim of this study was to evaluate the effectiveness, safety and economic cost of nivolumab in
Autor:
Eva, González-Haba-Peña, Margarita, Garrido-Siles, María Jose, Martínez-Bautista, Amparo, Burgos-San José, Azucena, Aldaz-Pastor, Irene, Mangues-Bafalluy
Publikováno v:
Farmacia Hospitalaria v.44 n.5 2020
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España: Revistas Científicas Españolas de Ciencias de la Salud
Instituto de Salud Carlos III (ISCIII)
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 192-197 (2020)
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España: Revistas Científicas Españolas de Ciencias de la Salud
Instituto de Salud Carlos III (ISCIII)
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 192-197 (2020)
To analyze the excipients and impurities contained in the various docetaxel products available on the market and find out whether they may be responsible for any of the different adverse events associated with the use of docetaxel in patients with br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c70f6c697ca78b4d7b65d1fd1e292e7f
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432020000500002
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432020000500002
Autor:
Margarita Garrido Siles, Julia Alcaide García, Elísabeth Pérez Ruíz, Jimena Abilés, Elena Álvaro Sanz, Antonio Rueda Domínguez
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 29(2)
Among the prognostic factors relevant to the condition of oncological patients, nutritional status (NS) has the greatest single impact on quality of life (QL). The goals of our study were to evaluate the influence of NS, weight loss (WL), and the pre
Publikováno v:
International Journal of Clinical Pharmacy. 36:1251-1259
Background Cancer patients are especially vulnerable to drug interactions, which may alter the efficacy and toxicity of treatment, leading to severe clinical consequences. Objective Determine the incidence of such interactions in patients receiving c
Autor:
María Teresa Garrido Martínez, Juan Francisco Marín Pozo, Carmen Martínez Díaz, Juan Manuel Duarte Pérez, José Carlos Roldán Morales, Margarita Garrido Siles, Ana I. Sánchez, Facundo Alberti Vargas, María José Martínez Bautista, Begoña Muros de Fuentes, María Dolores Alvarado Fernández, Pablo Nieto Guindo, Pedro Sánchez Rovira, Beatriz Mora Rodríguez, Silvia Maria Artacho Criado, Macarena Merino Almazán, Fátima Artime-Rodríguez-Hermida, María Paz Quesada Sanz
Publikováno v:
Journal of Clinical Oncology. 36:e21092-e21092
e21092Background: Nivolumab is recommended as a standard-of-care treatment in patients (pts) with progression to first-line therapy for non-smal-cell lung cancer (NSCLC). Our objective is to evalua...